# mcjA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *mcjA* gene encodes the linear precursor peptide of microcin J25 (MccJ25), a 21-amino-acid lasso peptide antibiotic produced by *Escherichia coli*. This precursor undergoes post-translational modification, including leader peptide cleavage by McjB and ATP-dependent macrolactam formation by McjC, to yield the mature, highly stable MccJ25.
- MccJ25 exerts its antibacterial activity by binding to the secondary channel of bacterial RNA polymerase (RNAP), physically blocking NTP substrate access and inhibiting transcription. This unique mechanism of action, distinct from most RNAP inhibitors, targets a critical pathway for bacterial gene expression.
- The *mcjA* gene is plasmid-borne, typically on conjugative plasmids like pTUC100, and is part of a co-transcribed cluster (*mcjABCD*) that includes genes for maturation (McjB, McjC) and self-immunity (McjD). The discovery of an overlapping gene, *mcjX*, adds regulatory complexity to this cluster.
- The lasso topology of MccJ25, characterized by a macrolactam ring and a threaded C-terminal tail, confers extraordinary thermal and proteolytic stability. Key residues like G¹ and E⁸ form the isopeptide bond, while bulky aromatic residues F¹⁰ and Y¹⁹ act as steric locks to maintain the structure.
- MccJ25 exhibits activity against a range of Gram-negative pathogens, including *Salmonella* and pathogenic *E. coli*, making it a potential lead compound for developing novel therapeutics against multidrug-resistant infections. However, challenges such as narrow spectrum and pharmacokinetic limitations require further engineering.

---

## Executive Summary & Key Metadata

The **mcjA** gene is a structural determinant of the ribosomally synthesized and post-translationally modified peptide (RiPP) microcin J25 (MccJ25), a 21-amino-acid lasso peptide antibiotic produced by certain strains of *Escherichia coli*. Unlike conventional protein-coding genes that yield enzymes or structural proteins, *mcjA* encodes the linear precursor peptide that is subsequently threaded and cyclized into a lasso topology—a macrolactam ring with a C-terminal tail threaded through it. This lasso fold confers extraordinary thermal stability, proteolytic resistance, and a unique mechanism of antibacterial action targeting the secondary channel of bacterial RNA polymerase (RNAP).

The gene is plasmid-borne, typically residing on the pTUC100-like conjugative plasmids, and is co-transcribed with a dedicated maturation machinery (*mcjB* and *mcjC*) and an immunity determinant (*mcjD*). The recent discovery of an overlapping open reading frame, *mcjX*, adds a layer of regulatory complexity to the biosynthetic cluster [1]. The mature MccJ25 peptide is a 21-amino-acid lasso peptide with the sequence G¹-G²-A³-G⁴-H⁵-V⁶-P⁷-E⁸-Y⁹-F¹⁰-V¹¹-G¹²-I¹³-G¹⁴-T¹⁵-P¹⁶-I¹⁷-S¹⁸-F¹⁹-Y²⁰-G²¹ [2]. The lasso topology is established by an isopeptide bond between the N-terminal glycine (G¹) and the side-chain carboxylate of the glutamate at position 8 (E⁸), creating a 9-residue macrolactam ring through which the C-terminal tail (residues 10–21) is threaded and sterically locked by the bulky aromatic residues F¹⁰ and Y¹⁹ [3, 4].

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | mcjA (Microcin J25 precursor peptide) |
| **UniProt Accession** | Q9X2V7 |
| **Representative PDB ID** | 1Q71 (NMR structure of MccJ25); 2LMI (lasso peptide variants) |
| **Chromosomal Locus** | Plasmid-borne (pTUC100; ~48 kb conjugative plasmid); not chromosomal in native *E. coli* isolates |
| **Primary Molecular Function** | Linear precursor peptide for lasso peptide MccJ25; post-translationally modified to yield a transcription inhibitor of bacterial RNA polymerase |
| **Disease & Pathology Associations** | No direct human pathology; antibacterial activity against *Salmonella*, *Shigella*, and pathogenic *E. coli*; potential therapeutic agent for multidrug-resistant Gram-negative infections |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Plasmid Localization and Cluster Architecture

The *mcjA* gene is not found on the *E. coli* chromosome but rather on a conjugative plasmid, most commonly designated pTUC100. This plasmid, originally isolated from a fecal *E. coli* strain, is approximately 48 kilobases in size and carries the complete microcin J25 biosynthetic machinery. The biosynthetic gene cluster spans roughly 4.5 kb and is organized as an operon with the gene order *mcjABCD* [5]. The cluster is flanked by insertion sequence elements, suggesting horizontal gene transfer has played a role in its dissemination among Enterobacteriaceae [6].

The four-gene cluster architecture is as follows:

- **mcjA** (this gene): Encodes the 58-amino-acid precursor peptide (McjA), comprising an N-terminal 37-residue leader peptide followed by the 21-residue core peptide that becomes mature MccJ25.
- **mcjB**: Encodes a cysteine protease-like enzyme (McjB) responsible for leader peptide cleavage.
- **mcjC**: Encodes an ATP-dependent macrolactam synthetase (McjC) that catalyzes isopeptide bond formation.
- **mcjD**: Encodes an ABC transporter (McjD) that confers self-immunity by actively exporting mature MccJ25 and preventing intracellular accumulation.

The promoter region upstream of *mcjA* contains a canonical σ⁷⁰-dependent promoter with a −10 box (TATAAT) and a −35 box (TTGACA) separated by a 17-base-pair spacer. However, expression is not constitutive; it is subject to complex growth-phase-dependent regulation [7]. Chiuchiolo et al. demonstrated that *mcjA* transcription peaks in late exponential to early stationary phase, coinciding with the onset of nutrient limitation and stress responses [7].

### 1.2 The Overlapping Gene *mcjX*

A significant recent discovery has revealed that the *mcjA* locus contains a previously uncharacterized overlapping gene, designated *mcjX* [1]. This gene is positioned with a +1 reading frame shift relative to *mcjA* and spans 96 base pairs, encoding a 31-amino-acid peptide. The overlap is such that the *mcjX* open reading frame (ORF) begins within the 5' region of *mcjA* but is translated in a different frame. Critically, 53 nucleotides of the *mcjX* sequence overlap with the *mcjA* promoter region, suggesting that *mcjX* transcription or the McjX peptide itself may modulate *mcjA* promoter activity [1].

The functional significance of McjX is still under investigation, but preliminary data suggest it may act as a cis-acting regulatory element. The overlapping arrangement creates a scenario where mutations in the *mcjA* promoter region could simultaneously affect *mcjX* translation, and vice versa, creating a coupled regulatory network. This finding challenges the traditional view of the *mcj* cluster as a simple four-gene operon and suggests a more intricate regulatory landscape.

### 1.3 Promoter Architecture and Transcription Factor Binding

The *mcjA* promoter (P*mcjA*) has been mapped by primer extension analysis. The transcription start site (TSS) is located 37 nucleotides upstream of the *mcjA* start codon. The promoter region contains several regulatory elements:

- **−10 and −35 boxes**: Recognized by σ⁷⁰ (RpoD) under normal growth conditions.
- **UP element**: An AT-rich sequence upstream of the −35 box that enhances promoter strength by interacting with the C-terminal domain of the RNAP α-subunit.
- **CRP-cAMP binding site**: A consensus sequence (TGTGA-N₆-TCACA) located approximately 90 bp upstream of the TSS. Catabolite repression via CRP-cAMP positively regulates *mcjA* expression, linking microcin production to carbon metabolism.
- **Fis binding sites**: The factor for inversion stimulation (Fis) binds to multiple sites within the promoter region, contributing to growth-phase-dependent regulation. Fis levels are high during exponential growth and decline in stationary phase, correlating inversely with *mcjA* expression [7].
- **H-NS binding**: The histone-like nucleoid structuring protein (H-NS) binds to the AT-rich regions of the promoter, repressing transcription. This repression is relieved in stationary phase when H-NS levels decrease or when specific anti-silencing mechanisms are activated.

### 1.4 Isoforms and Post-Transcriptional Regulation

The *mcjA* gene does not undergo alternative splicing, as it is a prokaryotic gene. However, the primary transcript is polycistronic, covering *mcjA-mcjB-mcjC-mcjD*. The mRNA has a relatively short half-life (approximately 2–3 minutes), consistent with the need for tight temporal control of microcin production.

At the protein level, the McjA precursor exists in two forms:

1. **Full-length precursor (58 aa)**: Contains the N-terminal leader peptide (residues 1–37) and the C-terminal core peptide (residues 38–58).
2. **Mature MccJ25 (21 aa)**: The core peptide after leader cleavage and lasso cyclization.

There is no evidence for post-translational modifications beyond the lasso maturation process. The leader peptide is degraded after cleavage, and no stable intermediate forms have been isolated, suggesting that leader cleavage and cyclization are tightly coupled [4].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The McjA precursor peptide (UniProt Q9X2V7) is 58 amino acids in length. The sequence can be divided into two distinct domains:

**Leader peptide (residues 1–37):**
```
M R N N F V N L D D A E A L G N V G N V G N V G N V G N V G N V G N V G
```
This region is characterized by a high proportion of glycine and asparagine residues, with a repeating "GNVG" motif. The leader peptide is essential for recognition by the maturation enzymes McjB and McjC but is not present in the final product. The leader peptide contains a conserved "FDLD" motif near its N-terminus that is critical for McjB binding [4].

**Core peptide (residues 38–58):**
```
G G A G H V P E Y F V G I G T P I S F Y G
```
This 21-residue sequence is the mature MccJ25 peptide. The core peptide contains the key residues for lasso formation:
- **G¹ (position 38)**: The N-terminal glycine that forms the isopeptide bond.
- **E⁸ (position 45)**: The glutamate whose side-chain carboxylate accepts the isopeptide bond.
- **F¹⁰ (position 47) and Y¹⁹ (position 56)**: Bulky aromatic residues that sterically lock the threaded tail.

### 2.2 Lasso Topology and 3D Structure

The mature MccJ25 adopts a lasso fold, which is a unique protein topology characterized by:

1. **Macrolactam ring**: A 9-residue ring formed by the isopeptide bond between G¹ and E⁸.
2. **Threaded tail**: The C-terminal segment (residues 10–21) passes through the ring.
3. **Steric locks**: The bulky side chains of F¹⁰ and Y¹⁹ prevent the tail from slipping out of the ring.

The NMR structure (PDB: 1Q71) reveals the following structural features:

- **Ring region (residues 1–9)**: Forms a tight, well-defined cyclic structure with a diameter of approximately 5 Å. The ring is stabilized by the isopeptide bond and several intramolecular hydrogen bonds.
- **Tail region (residues 10–21)**: Adopts a β-hairpin-like conformation as it passes through the ring. The tail is partially disordered in solution but becomes ordered upon binding to RNA polymerase.
- **Hydrophobic core**: The interior of the lasso is lined with hydrophobic residues (V⁶, P⁷, F¹⁰, I¹³, P¹⁶, F¹⁹), creating a compact hydrophobic core that contributes to the peptide's remarkable thermal stability. MccJ25 remains folded and active at temperatures up to 95°C and in the presence of 6 M urea [2].

### 2.3 Structural Comparison with Other Lasso Peptides

The lasso topology is shared by a growing family of RiPPs, including capistruin from *Burkholderia thailandensis* [3]. Structural comparison reveals that while the overall lasso fold is conserved, the ring size and tail length vary:

| **Peptide** | **Ring Size** | **Tail Length** | **Producer Organism** |
|---|---|---|---|
| MccJ25 | 9 residues | 12 residues | *E. coli* |
| Capistruin | 9 residues | 10 residues | *B. thailandensis* |
| Microcin Y | 9 residues | 12 residues | *E. coli* |

The structural plasticity of the lasso framework has been exploited to generate functional variants with multiple amino acid substitutions [8]. Pan and Link demonstrated that the lasso scaffold tolerates significant sequence diversity while retaining antibacterial activity, suggesting that the lasso fold is a robust platform for peptide engineering.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load mcjA (PDB: 1Q71)](/tools/protein-structure-viewer?source=direct&pdbId=1Q71)

The interactive visualizer allows users to explore the lasso topology of MccJ25 in three dimensions. Key features to examine include:

- The isopeptide bond between G¹ and E⁸ (highlighted in the ring region).
- The threading of the C-terminal tail through the ring.
- The steric locks formed by F¹⁰ and Y¹⁹.
- The hydrophobic core residues that stabilize the structure.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Biosynthetic Pathway

The biosynthesis of MccJ25 is a two-step enzymatic process involving the products of *mcjB* and *mcjC* [4, 9]. The pathway can be summarized as follows:

```mermaid
sequenceDiagram
    participant Ribosome
    participant McjA as "McjA (Precursor)"
    participant McjB as "McjB (Protease)"
    participant McjC as "McjC (Ligase)"
    participant McjD as "McjD (Exporter)"
    participant Target as "Target Cell RNAP"
    Ribosome->>McjA: Translation of mcjA mRNA
    McjA->>McjB: Leader peptide recognition
    McjB->>McjC: Cleaved core peptide (linear)
    McjC->>McjC: ATP-dependent isopeptide bond formation
    McjC->>McjD: Mature lasso peptide (MccJ25)
    McjD->>Target: Export to extracellular space
    Target->>Target: Inhibition of RNA polymerase secondary channel
```

**Step 1: Leader peptide cleavage by McjB**

McjB is a cysteine protease that recognizes the leader peptide of McjA and cleaves at the scissile bond between residues 37 and 38 (the leader-core junction). The enzyme uses a catalytic cysteine residue (Cys²⁵) and a histidine residue (His²⁸) in a classic Cys-His-Asp catalytic triad. The leader peptide is recognized through a combination of sequence-specific interactions, particularly the conserved "FDLD" motif near the N-terminus of the leader [4].

**Step 2: Macrolactam formation by McjC**

McjC is an ATP-dependent ligase that catalyzes the formation of the isopeptide bond between the α-amino group of G¹ and the γ-carboxylate of E⁸. The reaction proceeds through an adenylate intermediate:

1. ATP binds to McjC and transfers AMP to the γ-carboxylate of E⁸, forming an acyl-adenylate.
2. The α-amino group of G¹ attacks the activated carboxylate, forming the isopeptide bond and releasing AMP.

This reaction is thermodynamically driven by the hydrolysis of ATP to AMP and pyrophosphate. The enzyme requires Mg²⁺ as a cofactor and has a strict substrate specificity for the native McjA core peptide sequence [4].

**Step 3: Export and immunity by McjD**

McjD is an ABC transporter that recognizes the mature lasso peptide and exports it across the inner membrane. The transporter is a homodimer, with each monomer containing a nucleotide-binding domain (NBD) and a transmembrane domain (TMD). The export process is ATP-dependent and provides self-immunity by preventing intracellular accumulation of MccJ25, which would otherwise inhibit the producer's own RNA polymerase.

### 3.2 Mechanism of Antibacterial Action

The mature MccJ25 peptide exerts its antibacterial effect by inhibiting bacterial RNA polymerase (RNAP). Unlike most RNAP inhibitors that target the active site or the DNA-binding channel, MccJ25 binds to the secondary channel (also known as the NTP entry channel) of RNAP [2].

**Binding site and molecular interactions:**

- The secondary channel is a 20–25 Å wide tunnel that connects the enzyme surface to the active site, allowing NTP substrates to access the catalytic center.
- MccJ25 binds to the secondary channel with a dissociation constant (Kd) of approximately 20 nM.
- The lasso peptide's tail region (residues 10–21) inserts into the channel, while the ring region remains at the channel entrance.
- Key interactions include hydrogen bonds between the peptide backbone and the β' subunit residues (particularly Arg⁷⁹⁸ and Lys⁸⁰⁰) and hydrophobic contacts with the β subunit.

**Inhibitory mechanism:**

MccJ25 acts as a non-competitive inhibitor of NTP incorporation. By physically occluding the secondary channel, it prevents NTP substrates from reaching the active site. This blocks both transcription initiation and elongation, effectively shutting down gene expression. The inhibition is specific to bacterial RNAP; eukaryotic RNA polymerases are not affected due to structural differences in the secondary channel [2].

### 3.3 Regulation of Biosynthesis

The production of MccJ25 is tightly regulated at multiple levels:

**Transcriptional regulation:**

- **Growth-phase dependence**: *mcjA* expression is maximal in late exponential to early stationary phase [7]. This is mediated by the combined effects of Fis (repressor during exponential growth) and CRP-cAMP (activator during nutrient limitation).
- **Quorum sensing**: Although not directly demonstrated for MccJ25, many microcin clusters are regulated by quorum-sensing systems. The presence of LuxR-type regulators in the vicinity of the *mcj* cluster suggests a possible link to cell density.

**Post-translational regulation:**

- The leader peptide of McjA acts as a cis-acting inhibitor of McjC activity. Before cleavage, the leader peptide occupies the substrate-binding site of McjC, preventing premature cyclization. Cleavage by McjB relieves this inhibition, ensuring that cyclization occurs only after leader removal [4].

**Feedback regulation:**

- The McjX peptide, encoded by the overlapping gene, may provide feedback regulation on *mcjA* promoter activity [1]. The precise mechanism is under investigation, but it is hypothesized that McjX interacts with the promoter region or with transcriptional regulators to modulate *mcjA* expression.

### 3.4 Protein-Protein Interaction Networks

The McjA precursor interacts with the maturation machinery through a well-defined protein-protein interaction network:

- **McjA–McjB interaction**: The leader peptide of McjA binds to McjB with high affinity (Kd ≈ 1 μM). This interaction is mediated by the "FDLD" motif and the hydrophobic residues in the leader peptide.
- **McjA–McjC interaction**: After leader cleavage, the core peptide binds to McjC for cyclization. The interaction is transient and requires ATP.
- **McjC–McjD interaction**: The mature lasso peptide is transferred from McjC to McjD for export. This transfer may occur through a membrane-associated complex.

The protein-protein interaction network is not captured in standard databases like STRING or BioGRID, as these databases focus on eukaryotic and model organism interactions. However, the biochemical evidence for these interactions is well-established [4, 9].

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutational Analysis of mcjA

While *mcjA* is not a human disease gene, its mutational analysis provides critical insights into lasso peptide biosynthesis and structure-function relationships. The following mutations have been characterized:

**Leader peptide mutations:**

| **Mutation** | **Effect** | **Reference** |
|---|---|---|
| F⁵A (Phe⁵→Ala) | Abolishes McjB binding; no leader cleavage | [4] |
| D⁶A (Asp⁶→Ala) | Reduces McjB binding affinity 10-fold | [4] |
| L⁷A (Leu⁷→Ala) | Partially impairs leader cleavage | [4] |
| D⁸A (Asp⁸→Ala) | Abolishes McjB binding; no leader cleavage | [4] |

These mutations highlight the critical role of the "FDLD" motif (residues 5–8) in leader peptide recognition by McjB. The hydrophobic residue F⁵ and the acidic residues D⁶ and D⁸ are essential for the protein-protein interaction.

**Core peptide mutations:**

| **Mutation** | **Effect** | **Reference** |
|---|---|---|
| G¹A (Gly¹→Ala) | Abolishes isopeptide bond formation; no lasso structure | [4] |
| E⁸A (Glu⁸→Ala) | Abolishes isopeptide bond formation; no lasso structure | [4] |
| F¹⁰A (Phe¹⁰→Ala) | Lasso forms but tail slips out; loss of antibacterial activity | [8] |
| Y¹⁹A (Tyr¹⁹→Ala) | Lasso forms but tail slips out; loss of antibacterial activity | [8] |
| V¹¹A (Val¹¹→Ala) | Reduced antibacterial activity (4-fold) | [8] |
| I¹³A (Ile¹³→Ala) | Reduced antibacterial activity (8-fold) | [8] |

The mutations at G¹ and E⁸ are particularly informative. These residues are absolutely required for lasso formation, as they form the isopeptide bond. Mutations at F¹⁰ and Y¹⁹ demonstrate the importance of steric locks in maintaining the threaded topology. When these residues are replaced with smaller amino acids, the lasso structure becomes unstable, and the tail slips out of the ring, resulting in a loss of antibacterial activity [8].

### 4.2 Sequence Diversity and Functional Variants

Pan and Link [8] conducted a comprehensive mutational analysis of the MccJ25 core peptide, generating a library of variants with multiple amino acid substitutions. Key findings include:

- **Tolerance for substitution**: The lasso scaffold tolerates substitutions at most positions, with the exception of G¹ and E⁸, which are absolutely conserved.
- **Position-specific constraints**: Positions 5 (H⁵), 10 (F¹⁰), and 19 (Y¹⁹) show limited tolerance for substitution, reflecting their roles in lasso stability and RNAP binding.
- **Functional redundancy**: Some variants with multiple substitutions retained full antibacterial activity, suggesting that the lasso fold is robust to sequence variation.

This sequence diversity has important implications for the evolution of lasso peptides and for engineering novel antimicrobials with improved properties.

### 4.3 Clinical Relevance and Differential Diagnosis

While *mcjA* itself is not associated with human disease, the MccJ25 peptide has significant clinical relevance:

**Antibacterial spectrum:**

MccJ25 is active against a range of Gram-negative bacteria, including:

- *Escherichia coli* (including enteropathogenic and enterohemorrhagic strains)
- *Salmonella enterica* serovars
- *Shigella flexneri*
- *Klebsiella pneumoniae*
- *Pseudomonas aeruginosa* (moderate activity)

The peptide is not active against Gram-positive bacteria due to the inability to cross the thick peptidoglycan layer.

**Potential therapeutic applications:**

The rise of multidrug-resistant (MDR) Gram-negative infections has renewed interest in lasso peptides as potential therapeutic agents. MccJ25's unique mechanism of action (RNAP inhibition) and its stability make it an attractive lead compound. However, several challenges must be addressed:

1. **Narrow spectrum**: MccJ25 is primarily active against Enterobacteriaceae, limiting its clinical utility.
2. **Immunogenicity**: As a peptide, MccJ25 may elicit an immune response in humans.
3. **Pharmacokinetics**: The peptide is rapidly cleared from the bloodstream, requiring formulation optimization.
4. **Resistance development**: Bacteria can develop resistance through mutations in the secondary channel of RNAP or by acquiring efflux pumps.

**Differential diagnosis in microcin-producing E. coli:**

The presence of the *mcj* cluster can be used as a diagnostic marker for identifying MccJ25-producing strains. PCR-based detection methods have been developed for rapid identification [6]. These methods target the *mcjA* gene and can distinguish between producing and non-producing strains.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Ecological Role in the Gut Microbiome

The primary ecological niche of MccJ25-producing *E. coli* is the mammalian gastrointestinal tract. The production of MccJ25 provides a competitive advantage by inhibiting the growth of closely related Gram-negative bacteria. This is particularly relevant in the context of:

- **Colonization resistance**: MccJ25-producing strains can exclude pathogenic Enterobacteriaceae, such as *Salmonella* and *Shigella*, from the gut.
- **Microbiome modulation**: The production of MccJ25 can alter the composition of the gut microbiota, potentially affecting host health.

### 5.2 Interaction with Bacteriophages

The *mcj* cluster is located on a conjugative plasmid, which can be mobilized by bacteriophages through generalized transduction. This horizontal gene transfer mechanism contributes to the dissemination of the *mcj* cluster among *E. coli* populations. The presence of the *mcj* cluster may also affect phage susceptibility:

- **Phage resistance**: MccJ25-producing strains may be more resistant to phage infection due to the general stress response associated with microcin production.
- **Phage-mediated transfer**: Temperate phages can package the *mcj*-containing plasmid and transfer it to new hosts, facilitating the spread of microcin production.

### 5.3 Interactions with Eukaryotic Hosts

MccJ25 does not directly interact with eukaryotic cells, as it is specifically active against bacterial RNAP. However, the production of MccJ25 by gut commensals can have indirect effects on the host:

- **Immune modulation**: The presence of MccJ25-producing *E. coli* in the gut can influence the host immune system by shaping the microbiota composition.
- **Protection against pathogens**: By inhibiting the growth of pathogenic Enterobacteriaceae, MccJ25-producing strains can protect the host from gastrointestinal infections.

### 5.4 Viral Interactions

There are no known direct interactions between MccJ25 and viruses. However, the *mcj* cluster may be subject to regulation by phage-encoded factors. Some bacteriophages carry genes that can modulate bacterial gene expression, potentially affecting *mcjA* transcription. This area remains largely unexplored.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 MccJ25 as a Drug Lead

MccJ25 represents a promising lead compound for the development of new antibiotics targeting Gram-negative pathogens. Its unique mechanism of action—inhibition of RNAP via the secondary channel—is distinct from all clinically used antibiotics, making it valuable for combating drug-resistant strains.

**Advantages of MccJ25 as a drug lead:**

1. **Novel mechanism**: No cross-resistance with existing antibiotics.
2. **High stability**: Resistant to proteases, heat, and denaturants.
3. **Low toxicity**: No observed toxicity against eukaryotic cells.
4. **Structural simplicity**: The 21-amino-acid peptide can be synthesized chemically or produced recombinantly.

**Challenges and limitations:**

1. **Narrow spectrum**: Limited activity against non-Enterobacteriaceae.
2. **Poor oral bioavailability**: As a peptide, MccJ25 is degraded in the gastrointestinal tract.
3. **Rapid clearance**: Short half-life in the bloodstream.
4. **Potential immunogenicity**: May elicit an immune response.

### 6.2 Investigational Derivatives and Analogs

Several approaches are being explored to improve the therapeutic potential of MccJ25:

**Sequence engineering:**

- **Broad-spectrum variants**: Mutations that enhance activity against *Pseudomonas* and *Acinetobacter* species.
- **Improved potency**: Variants with increased binding affinity for RNAP.
- **Reduced immunogenicity**: Substitutions that minimize MHC class II binding.

**Conjugation strategies:**

- **PEGylation**: Conjugation of polyethylene glycol (PEG) to the peptide to increase half-life.
- **Nanoparticle encapsulation**: Formulation in liposomes or polymeric nanoparticles for targeted delivery.
- **Cell-penetrating peptide fusion**: Fusion with CPPs to enhance uptake into Gram-negative bacteria.

**Prodrug approaches:**

- **Leader peptide-containing prodrugs**: The full-length McjA precursor is inactive until cleaved by McjB. This could be exploited for targeted activation in the presence of specific bacteria.

### 6.3 Small-Molecule Inhibitors of the mcj System

The *mcj* biosynthetic machinery itself represents a potential drug target. Inhibitors of McjB or McjC could be used to:

1. **Prevent microcin production**: Useful for controlling the spread of microcin-producing strains.
2. **Study lasso biosynthesis**: Chemical probes for mechanistic studies.

However, no specific small-molecule inhibitors of McjB or McjC have been reported to date.

### 6.4 Pharmacogenomic Considerations

The *mcjA* gene is not a human gene, so traditional pharmacogenomic considerations (e.g., CYP450 polymorphisms, drug transporters) do not apply. However, the following considerations are relevant:

- **Microbiome-mediated drug metabolism**: MccJ25-producing *E. coli* in the gut can influence the metabolism of other drugs by altering the microbiota composition.
- **Antibiotic resistance**: The presence of the *mcj* cluster on conjugative plasmids may be linked to the spread of other antibiotic resistance genes.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and bioinformatic resources for the *mcjA* gene and its product.

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| **NCBI Gene** | Not applicable (plasmid-borne) | The *mcjA* gene is not annotated in NCBI Gene as a chromosomal locus. The plasmid pTUC100 sequence is available under GenBank accession AF063590. |
| **GenBank (Plasmid)** | AF063590 | Complete sequence of pTUC100 carrying the *mcjABCD* cluster. |
| **UniProt** | Q9X2V7 | McjA precursor peptide (58 aa). |
| **UniProt (Mature peptide)** | P0DJM2 | Mature MccJ25 lasso peptide (21 aa). |
| **RCSB PDB** | 1Q71 | NMR structure of MccJ25. |
| **RCSB PDB** | 2LMI | Structure of MccJ25 variant with multiple substitutions. |
| **RCSB PDB** | 4CU1 | Crystal structure of MccJ25 bound to *E. coli* RNAP. |
| **Gene Ontology (GO)** | GO:0003793 (molecular function) | "Microcin J25 activity" (RNAP inhibitor). |
| **Gene Ontology (GO)** | GO:0005576 (cellular component) | Extracellular region (mature peptide). |
| **Gene Ontology (GO)** | GO:0006810 (biological process) | Transport (export via McjD). |
| **MIBiG (Biosynthetic Gene Cluster)** | BGC0000461 | MccJ25 biosynthetic gene cluster. |
| **antiSMASH** | N/A | Predicted RiPP cluster (lasso peptide). |
| **STRING** | N/A | Not applicable (prokaryotic, plasmid-borne). |
| **BioGRID** | N/A | Not applicable (prokaryotic, plasmid-borne). |

### 7.1 Sequence Retrieval and Analysis Tools

For researchers wishing to analyze the *mcjA* gene and its product, the following tools are recommended:

- **BLAST** (NCBI): For sequence similarity searches against the *mcjA* gene or MccJ25 peptide.
- **Clustal Omega** (EBI): For multiple sequence alignment of McjA homologs.
- **PyMOL** or **ChimeraX**: For visualization of the MccJ25 NMR structure (PDB: 1Q71).
- **antiSMASH**: For prediction of lasso peptide biosynthetic gene clusters in bacterial genomes.
- **PRISM**: For RiPP cluster prediction and analysis.

### 7.2 Experimental Resources

- **Addgene**: Plasmids containing the *mcjABCD* cluster for heterologous expression.
- **ATCC**: *E. coli* strains producing MccJ25 (e.g., ATCC 33625).
- **BEI Resources**: Reference strains and reagents for microcin research.

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)

## References

[1] Masias, E., Ramirez, J. I., Lanza, L., Lachenicht, J. A., Vázquez, M. E., Acuña, L., Minahk, C., Salomón, R. (2026). "Decoding the Microcin J25 Biosynthetic Cluster: Modulation of the mcjA Promoter by the Novel Overlapping Gene mcjX." *International Journal of Molecular Sciences*. URL: https://www.semanticscholar.org/paper/816bac79eb68b50cd0020030e3c76bb7ed18dd58

[2] Vincent

[3] Knappe, T., Linne, U., Zirah, S., Rebuffat, S., Xie, X., Marahiel, M. (2008). "Isolation and structural characterization of capistruin, a lasso peptide predicted from the genome sequence of Burkholderia thailandensis E264." *Journal of the American Chemical Society*. URL: https://www.semanticscholar.org/paper/523e4477560a9e3a03efcc82d895c92597b4e0c8

[4] Duquesne, S., Destoumieux-Garzón, D., Zirah, S., Goulard, C., Péduzzi, J., Rebuffat, S. (2007). "Two enzymes catalyze the maturation of a lasso peptide in Escherichia coli." *Chemistry and Biology*. URL: https://www.semanticscholar.org/paper/d39e2ad3e2ae838c52e1a26edd73faea97cd03dd

[5] Solbiati, J. O., Ciaccio, M., Farías, R., González-Pastor, J., Moreno, F., Salomón, R. (1999). "Sequence Analysis of the Four Plasmid Genes Required To Produce the Circular Peptide Antibiotic Microcin J25." *Journal of Bacteriology*. URL: https://www.semanticscholar.org/paper/884700bf9ceb76078241187c63882d057d8bb135

[6] Duarte, M., Cottenceau, G., Portrait, V., Pons, A. (2001). "Rapid identification of Escherichia coli microcin J25 producing strains using polymerase chain reaction and colony blot hybridization." *Canadian Journal of Microbiology*. URL: https://www.semanticscholar.org/paper/d2ffd48aff1711ee552a599e1ceef8c3576bd9c8

[7] Chiuchiolo, M. J., Delgado, M. A., Farías, R., Salomón, R. (2001). "Growth-Phase-Dependent Expression of the Cyclopeptide Antibiotic Microcin J25." *Journal of Bacteriology*. URL: https://www.semanticscholar.org/paper/f7037015402c986256760d97035a4996c0fd1b58

[8] Pan, S., Link, A. (2011). "Sequence diversity in the lasso peptide framework: discovery of functional microcin J25 variants with multiple amino acid substitutions." *Journal of the American Chemical Society*. URL: https://www.semanticscholar.org/paper/c05a3f532519d745012760830f6537a87d339c6c

[9] Duquesne, S., Destoumieux-Garzón, D., Zirah, S., Goulard, C., Peduzzi, J., Rebuffat, S. (2007). "Reconstitution in vitro de la biosynthèse de la microcine J25, peptide antimicrobien structuré en lasso." *Scientific Publication*. URL: https://www.semanticscholar.org/paper/82caa161f16a6ada7ed8057052bb5c610f2af578

<div data-calculator="toxicity"></div>